CLIA Certified Lab selected - Pivotal US Clinical Validation
Filed with ASX · · 3 pages · English
Summary by 6ix AI
CLEO Diagnostics Ltd has announced the selection of a CLIA-certified laboratory, Asuragen, for its pivotal U.S. clinical validation program for a pre-surgical ovarian cancer test. The program aims to generate clinical performance data from a significant number of samples to establish key metrics such as sensitivity and specificity of the test. The results from this validation will support the company's planned FDA submission targeted for the first half of the upcoming year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from CLEO Diagnostics
- CLEO Receives First Batch of Commercial Test Kits
- Appendix 4E and 2026 Annual Report
- CLEO Enters Analytical Validation Phase
- CLEO Establishes U.S. Reimbursement Pathway
- CLEO Commences Kit Manufacturing Ahead of FDA Submission
Later from CLEO Diagnostics
- CLEO Commences Ovarian Cancer Screening Test Development
- Cleo Files Patents for its Ovarian Cancer Screening Test
- CLEO Commences Analytical Validation Ahead of FDA Submission
- CLEO Screening Test Meets Rigorous Performance Targets
- Quarterly activities and cashflow report
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics